Wellington Management Group LLP Has $71.06 Million Stock Position in Prothena Co. plc (NASDAQ:PRTA)

Wellington Management Group LLP increased its holdings in shares of Prothena Co. plc (NASDAQ:PRTA - Free Report) by 22.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,130,876 shares of the biotechnology company's stock after acquiring an additional 952,088 shares during the quarter. Wellington Management Group LLP owned about 9.53% of Prothena worth $71,063,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of Prothena by 11.5% during the 4th quarter. Vanguard Group Inc. now owns 1,403,838 shares of the biotechnology company's stock worth $19,443,000 after acquiring an additional 144,737 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Prothena by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 864,833 shares of the biotechnology company's stock valued at $11,980,000 after purchasing an additional 10,783 shares during the period. Federated Hermes Inc. boosted its stake in Prothena by 84.3% in the 4th quarter. Federated Hermes Inc. now owns 746,177 shares of the biotechnology company's stock valued at $10,335,000 after purchasing an additional 341,274 shares during the period. Boxer Capital Management LLC bought a new stake in Prothena in the 4th quarter valued at $9,556,000. Finally, Finepoint Capital LP boosted its stake in Prothena by 51.6% in the 4th quarter. Finepoint Capital LP now owns 657,071 shares of the biotechnology company's stock valued at $9,100,000 after purchasing an additional 223,600 shares during the period. 97.08% of the stock is owned by institutional investors and hedge funds.

Prothena Stock Up 1.5%

Shares of NASDAQ:PRTA traded up $0.07 during trading on Monday, reaching $4.66. 1,775,124 shares of the company traded hands, compared to its average volume of 691,595. The company's 50 day moving average is $8.70 and its two-hundred day moving average is $12.36. The firm has a market capitalization of $250.83 million, a PE ratio of -2.03 and a beta of 0.11. Prothena Co. plc has a 52 week low of $4.32 and a 52 week high of $25.42.

Prothena (NASDAQ:PRTA - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biotechnology company reported ($1.12) EPS for the quarter, missing analysts' consensus estimates of ($0.92) by ($0.20). Prothena had a negative return on equity of 22.67% and a negative net margin of 90.50%. The business had revenue of $2.83 million for the quarter, compared to analyst estimates of $8.18 million. During the same period last year, the firm posted ($1.34) EPS. Prothena's quarterly revenue was up 5500.0% on a year-over-year basis. As a group, research analysts anticipate that Prothena Co. plc will post -4.04 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on PRTA. Chardan Capital reduced their price target on Prothena from $40.00 to $18.00 and set a "buy" rating for the company in a research note on Tuesday, May 27th. Piper Sandler reduced their price target on Prothena from $110.00 to $81.00 and set an "overweight" rating for the company in a research note on Tuesday, May 27th. Jefferies Financial Group downgraded Prothena from a "buy" rating to a "hold" rating and set a $6.00 price target for the company. in a research note on Tuesday, May 27th. Royal Bank of Canada reduced their price target on Prothena from $24.00 to $20.00 and set a "sector perform" rating for the company in a research note on Friday, February 21st. Finally, Cantor Fitzgerald downgraded Prothena from an "overweight" rating to a "neutral" rating in a research note on Tuesday, May 27th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $31.50.

Prothena Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.